No headlines found.
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
PRNewswire (Wed, 27-Mar 8:36 AM ET)
PRNewswire (Wed, 20-Mar 8:54 AM ET)
PRNewswire (Thu, 7-Mar 7:54 AM ET)
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
PRNewswire (Thu, 1-Feb 8:00 AM ET)
Business Wire (Tue, 30-Jan 8:30 AM ET)
Business Wire (Mon, 8-Jan 8:30 AM ET)
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
Business Wire (Fri, 5-Jan 8:30 AM ET)
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders' Equity Requirement
Business Wire (Tue, 2-Jan 8:30 AM ET)
Aditxt Announces $6 Million Private Placement Priced At-The-Market under Nasdaq Rules
Business Wire (Fri, 29-Dec 5:07 PM ET)
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes a tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.
Aditxt trades on the NASDAQ stock market under the symbol ADTX.
As of March 28, 2024, ADTX stock price climbed to $3.05 with 61,147 million shares trading.
ADTX has a beta of 3.38, meaning it tends to be more sensitive to market movements. ADTX has a correlation of 0.04 to the broad based SPY ETF.
ADTX has a market cap of $5.08 million. This is considered a Sub-Micro Cap stock.
Last quarter Aditxt reported $124,486 in Revenue and -$48.77 earnings per share. This fell short of revenue expectation by $-175,514 and missed earnings estimates by -$42.78.
In the last 3 years, ADTX stock traded as high as $7,900.00 and as low as $2.95.
The top ETF exchange traded funds that ADTX belongs to (by Net Assets): VXF.
ADTX has underperformed the market in the last year with a price return of -91.2% while the SPY ETF gained +33.7%. ADTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -35.2% and -19.1%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
ADTX support price is $2.89 and resistance is $3.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADTX stock will trade within this expected range on the day.